Bailard, Inc. Cardiff Oncology, Inc. Transaction History

Bailard, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 25, 2022	SELL	$2.11 - $7.25 $56,970 - $195,750	-27,000 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$5.18 - $7.24 $11,396 - $15,928	-2,200 Reduced 7.53%	27,000 $162,000
Q3 2021 Nov 15, 2021	BUY	$5.01 - $7.58 $74,148 - $112,184	14,800 Added 102.78%	29,200 $194,000
Q2 2021 Aug 13, 2021	BUY	$6.65 - $10.04 $95,760 - $144,576	14,400 New	14,400 $96,000

12.4M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $195M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.